2025-10-19 - Analysis Report
Okay, here's an analysis of Schrodinger Inc. (SDGR) based on the provided data.

## SDGR Stock Analysis

**0. Overview:**

This report analyzes the performance of Schrodinger Inc. (SDGR) and provides insights into its financial health, market sentiment, and future prospects.

**1. Performance vs. S&P 500 (VOO):**

*   **Ticker:** SDGR
*   **Company:** Schrodinger Inc. (A company focused on computational drug discovery and materials science.)
*   **SDGR Cumulative Return:** -53.64%
*   **VOO Cumulative Return:** 65.21%
*   **Divergence:**
    *   Max: 42.2
    *   Min: -120.9
    *   Current: -117.9
    *   Relative Divergence: 1.8

    **Analysis:** SDGR has significantly underperformed the S&P 500 (VOO) over the period. The current divergence is near the minimum observed, indicating substantial underperformance. The relative divergence of 1.8 suggests that SDGR is currently positioned near the bottom of its historical divergence range relative to the S&P 500.

    **Alpha, Beta Analysis:**

| Year       | CAGR     | MDD    | Alpha    | Beta   | Cap(B) |
|------------|----------|--------|----------|--------|--------|
| 2020-2022  | -70.0%   | 78.2%  | -76.0%   | 0.0    | 1.4    |
| 2021-2023  | -57.0%   | 81.0%  | -59.0%   | -0.0   | 2.6    |
| 2022-2024  | 6.0%    | 81.0%  | -14.0%   | -0.0   | 1.4    |
| 2023-2025  | -2.0%   | 82.6%  | -63.0%   | -0.0   | 1.4    |

    **Analysis:**

    *   **CAGR:** The Compound Annual Growth Rate (CAGR) shows negative returns over the analyzed periods, except for 2022-2024, which has a small positive return.
    *   **MDD:** The Maximum Drawdown (MDD) is consistently high, indicating significant volatility and potential risk.
    *   **Alpha:** Negative Alpha values indicate that SDGR has underperformed relative to its benchmark (S&P 500).
    *   **Beta:** Beta values close to zero suggest that SDGR's price movements are not strongly correlated with the overall market. This could mean that its performance is more driven by company-specific factors rather than broader market trends.
    *   **Cap:** The capitalization is relatively constant (between 1.4B to 2.6B) over these time periods

**2. Recent Price Action:**

*   **Current Price:** 19.31
*   **Previous Close:** 20.31
*   **Change:** -4.92%
*   **5-day Moving Average:** 19.87
*   **20-day Moving Average:** 19.95
*   **60-day Moving Average:** 19.71

    **Analysis:** The stock price decreased by 4.92% compared to the previous close. All moving averages are hovering around the $20 mark, showing little trend.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.5 (Low Investment)
*   **RSI:** 48.59
*   **PPO:** -0.2994
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (47 shares - Very Safe - MRI:0.90) Monthly invest 1.4% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **20-day Relative Divergence Change:** +0.3 (Short-term increase)
*   **Expected Return:** -3380.6%

    **Analysis:**

    *   The Market Risk Indicator (MRI) suggests a low investment recommendation, indicating moderate risk.
    *   The RSI is neutral, implying neither overbought nor oversold conditions.
    *   The PPO being negative indicates a short-term downtrend.
    *   The Hybrid Signal suggests buying a full allocation with 0% cash reserve, indicating confidence and a very safe classification with an MRI of 0.90.
    *   The +0.3 change in relative divergence shows a short-term increase in the relative performance.
    *   The **significant price drop of -4.92% reflects a recent negative market reaction** and should be considered when assessing risk.
    *   The negative Expected Return indicates significant underperformance compared to S&P 500 in a long-term investment horizon.

**4. Recent News & Events:**

*   **Oct 15, 2025:** Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
*   **Sep 11, 2025:** Evaluating Valuation as Market Sentiment Remains Quiet
*   **Sep 09, 2025:** Potential to Rally 40.43% (Analyst Expectation)
*   **Aug 27, 2025:** Presentation at Morgan Stanley Global Healthcare Conference
*   **Aug 14, 2025:** Discontinuation of SGR-2921 Program

    **Analysis:**

    *   The news is mixed. Analyst reports suggest potential upside (40.43% rally), but the discontinuation of the SGR-2921 program is a setback.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy (~1.56)
*   **Opinions:** 10
*   **Target Price:**
    *   Average: 27.00
    *   High: 33.00
    *   Low: 19.00

    **Analysis:** Analysts have a positive consensus on SDGR, with an average target price of $27, suggesting potential upside from the current price.

**5. Recent Earnings Analysis:**

| 날짜       | EPS   | 매출        |
|------------|-------|-------------|
| 2025-08-06 | -0.59 | 0.05 B$     |
| 2025-05-07 | -0.82 | 0.06 B$     |
| 2024-11-12 | -0.52 | 0.04 B$     |
| 2024-07-31 | -0.74 | 0.05 B$     |
| 2025-08-06 | -0.74 | 0.05 B$     |

    **Analysis:** SDGR has consistently reported negative EPS and relatively stable revenue over the recent quarters. This indicates ongoing losses, which is a concern.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $0.05B    | 47.77%        |
| 2025-03-31 | $0.06B    | 52.26%        |
| 2024-12-31 | $0.09B    | 72.61%        |
| 2024-09-30 | $0.04B    | 50.24%        |
| 2024-06-30 | $0.05B    | 66.20%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $0.34B    | -12.59%   |
| 2025-03-31 | $0.37B    | -16.01%   |
| 2024-12-31 | $0.42B    | -9.54%    |
| 2024-09-30 | $0.45B    | -8.49%    |
| 2024-06-30 | $0.47B    | -11.40%   |

    **Analysis:**

    *   Revenue is relatively stable. Profit margins are healthy but inconsistent.
    *   Equity has been declining, and the Return on Equity (ROE) is consistently negative, reflecting net losses.

**7. Overall Summary:**

SDGR has significantly underperformed the S&P 500, with a large negative cumulative return difference. The financial data reveals ongoing losses with negative ROE and declining equity, though with positive profit margins. The stock price has recently decreased. Analyst consensus is positive, but the news is mixed.

**Recommendation:**

The data presents a mixed picture. While analysts are optimistic and the Hybrid Signal suggests buying now with full cash allocation, negative earnings, ROE, and underperformance against the S&P 500 raise concerns. Recent news and events also reflect both potential positives and negatives.

Given the low investment recommendation from MRI and the negative Expected Return, a cautious approach is advisable. Further research is needed to assess the potential for long-term profitability and sustainable revenue growth before considering a significant investment. Monitor future earning reports.
